Squamous Cell Carcinoma of the Head and Neck Clinical Trials

236 clinical trials for Squamous Cell Carcinoma of the Head and Neck across international registries, including 32 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors — RECRUITING · PHASE1
• Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer — RECRUITING · PHASE2
• Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib. — RECRUITING · PHASE2
• Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC — RECRUITING · PHASE2
• Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer — RECRUITING · PHASE1
• Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer — RECRUITING · PHASE1
• ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation — RECRUITING
• Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas — RECRUITING
• Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer — RECRUITING · PHASE2
• Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer — RECRUITING
• Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 — RECRUITING · PHASE1
• A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PETOSEMTAMAB PLUS PEMBROLIZUMAB VS PEMBROLIZUMAB IN FIRST-LINE TREATMENT OF RECURRENT OR METASTATIC PD-L1+ HEAD AND NECK SQUAMOUS CELL CARCINOMA. — RECRUITING · PHASE3
• A PHASE 3 OPEN-LABEL, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PETOSEMTAMAB COMPARED WITH INVESTIGATOR¿S CHOICE MONOTHERAPY TREATMENT IN PREVIOUSLY TREATED PATIENTS WITH INCURABLE, METASTATIC/RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA — RECRUITING · PHASE3
• A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF FICLATUZUMAB IN COMBINATION WITH CETUXIMAB IN PARTICIPANTS WITH RECURRENT OR METASTATIC (R/M) HPV-NEGATIVE HEAD AND NECK SQUAMOUS CELL CARCINOMA (FIERCE-HN) — RECRUITING · PHASE3
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE DOSTARLIMAB AS SEQUENTIAL THERAPY AFTER CHEMORADIATION IN PARTICIPANTS WITH LOCALLY ADVANCED UNRESECTED HEAD AND NECK SQUAMOUS CELL CARCINOMA — RECRUITING · PHASE3
• Collection of Plasma Samples for Squamous Cell Carcinoma of the Head and Neck Patients — RECRUITING
• A PHASE III, RANDOMIZED, OPEN-LABEL, MULTI-CENTER, GLOBAL STUDY OF VOLRUSTOMIG (MEDI5752) AS SEQUENTIAL THERAPY VERSUS OBSERVATION IN PARTICIPANTS WITH UNRESECTED LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA, WHO HAVE NOT PROGRESSED FOLLOWING DEFINITIVE CONCURRENT CHEMORADIOTHERAPY (EVOLVE-HNSCC) — RECRUITING · PHASE3
• A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTOCOL TO EVALUATE NOVEL IMMUNOTHERAPY COMBINATIONS AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH RECURRENT/METASTATIC PD-L1 POSITIVE SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK — RECRUITING · PHASE2
• A PHASE 3 (PIVOTAL STAGE) STUDY OF NBTXR3 ACTIVATED BY INVESTIGATOR'S CHOICE OF RADIOTHERAPY ALONE OR RADIOTHERAPY IN COMBINATION WITH CETUXIMAB FOR PLATINUM-BASED CHEMOTHERAPY-INELIGIBLE ELDERLY PATIENTS WITH LOCALLY ADVANCED HEAD & NECK SQUAMOUS CELL CARCINOMA — RECRUITING · PHASE3
• AN OPEN LABEL PHASE II RANDOMIZED TRIAL OF BNT113 IN COMBINATION WITH PEMBROLIZUMAB VERSUS PEMBROLIZUMAB MONOTHERAPY AS A FIRST LINE THERAPY IN PATIENTS WITH UNRESECTABLE RECURRENT, OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) WHICH IS POSITIVE FOR HUMAN PAPILLOMA VIRUS 16 (HPV16+) AND EXPRESSES PD-L1 — RECRUITING · PHASE2
• Evaluation of 18F-MISO-PET detectable changes in proliferation and dispersion of hypoxic subvolume in head and neck cancer in patients undergoing radio(chemo)therapy — RECRUITING
• A RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED, PHASE 3 STUDY OF DEBIO 1145 IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY AND STANDARD FRACTIONATION INTENSITY-MODULATED RADIOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK, SUITABLE FOR DEFINITIVE CHEMORADIOTHERAPY (TRILYNX) — RECRUITING · PHASE3
• A PHASE 4, SINGLE-ARM, OPEN-LABEL CLINICAL STUDY OF PEMBROLIZUMAB (MK-3475) TO EVALUATE THE EFFICACY AND SAFETY OF MK-3475 PLUS CARBOPLATIN AND PACLITAXEL AS FIRST-LINE TREATMENT OF RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (KEYNOTE-B10) — RECRUITING · PHASE4
• A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GKS3359609 IN COMBINATION WITH PEMBROLIZUMAB AND 5FU-PLATINUM CHEMOTHERAPY VERSUS PLACEBO IN COMBINATION WITH PEMBROLIZUMAB PLUS 5FU-PLATINUM CHEMOTHERAPY FOR FIRST-LIN TREATMENT OF RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA — RECRUITING · PHASE2
• "A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTICENTER, GLOBAL STUDY OF MONALIZUMAB OR PLACEBO IN COMBINATION WITH CETUXIMAB IN PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK PREVIOUSLY TREATED WITH AN IMMUNE CHECKPOINT I." — RECRUITING · PHASE3
• A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND CLINICAL STUDY OF PEMBROLIZUMAB (MK-3475) WITH OR WITHOUT LENVATINIB (E7080/MK- 7902) TO EVALUATE THE SAFETY AND EFFICACY OF PEMBROLIZUMAB AND LENVATINIB AS 1L INTERVENTION IN A PD-L1 SELECTED POPULATION OF PARTICIPANTS WITH RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (R/M HNSCC) (LEAP-010). — RECRUITING · PHASE3
• A STUDY TO EVALUATE THE SAFETY AND FEASIBILITY OF THE COMBINED USE OF NIVOLUMAB WITH PEMETREXED FOR THE TREATMENT OF ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK — RECRUITING
• A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 OR PLACEBO IN COMBINATION WITH PEMBROLIZUMAB FOR FIRST-LINE TREATMENT OF PD-L1 POSITIVE RECURRENT/METASTATICS HEAD AND NECK SQUAMOUS CELL CARCINOMA — RECRUITING · PHASE2
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF NIVOLUMAB OR NIVOLUMAB PLUS CISPLATIN, IN COMBINATION WITH RADIOTHERAPY IN PARTICIPANTS WITH CISPLATIN INELIGIBLE AND CISPLATIN ELIGIBLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) — RECRUITING · PHASE3
• A PHASE III, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE PEMBROLIZUMAB AS NEOADJUVANT THERAPY AND IN COMBINATION WITH STANDARD OF CARE AS ADJUVANT THERAPY FOR STAGE III-IVA RESECTABLE LOCOREGIONALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA (LA HNSCC) — RECRUITING · PHASE3
• A RANDOMIZED PHASE III STUDY OF PEMBROLIZUMAB GIVEN CONCOMITANTLY WITH CHEMORADIATION AND AS MAINTENANCE THERAPY VERSUS CHEMORADIATION ALONE IN SUBJECTS WITH LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA (KEYNOTE-412) — RECRUITING · PHASE3
• A DOUBLE-BLIND, RANDOMIZED, TWO ARM PHASE 2 STUDY OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS NIVOLUMAB IN COMBINATION WITH IPILIMUMAB PLACEBO SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) — RECRUITING · PHASE2
• Chemotherapy with paclitaxel and capecitabine for the treatment of recurrent or metastatic head and neck cancer — ACTIVE_NOT_RECRUITING · PHASE2
• A study to investigate patritumab in combination with cetuximab plus platinum-containing therapies in patients with head and neck cancer — COMPLETED · PHASE2
• Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma — COMPLETED · PHASE2
• CIML NK Cell in Head & Neck Cancer — COMPLETED · PHASE1
• VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy — ACTIVE_NOT_RECRUITING
• Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors — COMPLETED · PHASE2
• A PHASE 1/2, OPEN-LABEL TRIAL TO EVALUATE SAFETY, IMMUNOGENICITY, AND ANTI-TUMOR ACTIVITY OF VB10.16 IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH UNRESECTABLE RECURRENT OR METASTATIC HPV16-POSITIVE HEAD AND NECK SQUAMOUS CELL CARCINOMA — NOT_YET_RECRUITING · PHASE1
• Prevalence of Liver Fibrosis and Cirrhosis in Patients With Squamous Cell Carcinoma of the Head and Neck — TERMINATED · NA
• Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. — COMPLETED · PHASE1
• Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer — ACTIVE_NOT_RECRUITING · PHASE3
• Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC — TERMINATED · PHASE2
• Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors — TERMINATED · PHASE2
• A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study — COMPLETED · PHASE2
• A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors — TERMINATED · PHASE1
• Ipilimumab for Head and Neck Cancer Patients — ACTIVE_NOT_RECRUITING · PHASE1
• A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies — TERMINATED · PHASE1

Refine this search